Study of Microvascular Resistance Index in Heart Transplant Patients During the First Year to Guide Treatment and Improve Outcomes
Led by Hospital Miguel Servet · Updated on 2025-11-21
100
Participants Needed
2
Research Sites
20 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of the index of microvascular resistance IMR to monitor heart transplant patients during their first year after surgery. The study aims to assess whether IMR can help detect acute allograft rejection and predict long-term outcomes, potentially reducing the need for invasive biopsies. This observational study follows patients undergoing heart transplantation, focusing on improving surveillance and management based on microvascular function measurements.
The study involves coronary physiological assessments within the first three months and again at one year after transplant. Measurements include IMR, coronary flow reserve CFR, and fractional flow reserve FFR using a sensor-tipped guidewire in the coronary arteries. Depending on the IMR value, patient management may be adjusted, such as changing biopsy frequency or immunosuppressive therapy, although final decisions rest with the treating physician. Patients are grouped by their IMR value measured early after transplantation.
Participants will be monitored through clinical evaluations, lab tests, and event tracking at one month, one year, and up to five years. Data collected includes biopsy numbers, rejection episodes, cardiac events, and therapy adjustments. All information is anonymized and securely stored in a dedicated database. The primary outcome is IMR values at three months and one year, with long-term follow-up measuring rejection, vasculopathy, mortality, and heart failure. The study seeks to improve patient care by integrating physiological measurements into post-transplant monitoring.
CONDITIONS
Brief Title
IMR-Heart Trasplant Study
Research Team
G
Georgina Fuertes, MD PHD
A
Ainhoa Perez Guerrero, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients who have received and signed informed consent
You will not qualify if you...
Patients with hemodynamic instability after heart transplant, including cardiogenic shock or severe coagulopathy
Patients with acute cellular rejection before intracoronary physiological assessment
Patients with bronchial asthma or bronchopathy with a positive bronchodilation test, contraindicating adenosine use
Patients with epicardial coronary lesions with resting physiological index ≤0.89 or ≤0.80 at hyperemia
Patients unlikely to cooperate or unable/unwilling to give informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Within the first 3 months after heart transplant
Participants undergo coronary physiological assessment including measurement of index of microvascular resistance (IMR), coronary flow reserve (CFR), and fractional flow reserve (FFR) using intracoronary pressure and temperature sensor-tipped guidewire within the first three months post-heart transplant.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 5 years
Participants are observed with clinical condition, laboratory findings, and clinical events assessed at one month and one year after heart transplant. Follow-up monitoring continues for up to five years to evaluate cardiac events and management changes based on IMR values.
Visits at 1 month, 1 year, and additional follow-ups up to 5 years
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Swedish National Study on Donor-Derived Cell-Free DNA to Monitor Rejection After Heart Transplantation
Study of Microvascular Resistance Index in Heart Transplant Patients During the First Year to Guide Treatment and Improve Outcomes
Mobile Video Directly Observed Therapy to Improve Immunosuppression Medication Adherence in Adolescent Heart Transplant Patients
A Randomized Study to Enhance Medication Use and Patient Outcomes Using the eMocha DOT App
Trifecta-Heart Study Comparing Donor-Derived Cell-Free DNA Blood Test With Molecular Microscope Gene Expression and HLA Antibody Testing for Heart Transplant Rejection
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match.
Kiran K Khush, Wida S Cherikh, Daniel C Chambers...
The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure.
Lars H Lund, Leah B Edwards, Anna Y Kucheryavaya...